Breakthrough Study Led by Rethink Breast Cancer Board Member TORONTO, June 4, 2012 /CNW/ - Today Rethink Breast Cancer (Rethink) celebrates new study results that bring

A clinical trial of an experimental new breast cancer treatment found that it extended the life expectancy of patients without the symptoms of the disease worsening.

Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy.

MOUNTAIN VIEW, Calif., May 16, 2012 /PRNewswire/ -- Although there are approximately 27 drugs on the market indicated for the treatment of breast cancer, there is currently

In a paper published today in the journal Cell, a team from the University of North Carolina at Chapel Hill unveils the first broad-based test for activation of protein kinases "en masse", enabling measurement of the mechanism behind drug-resistant cancer and rational prediction of successful combination therapies.